Trevi Therapeutics Q2 net loss $12.4M; RIVER trial ~80% enrolled, topline Q4 2024

Trevi Therapeutics, Inc.

2024-Q2 EPS reported -$0.23

Q2 2024 net loss of $12.4M vs $7.1M in Q2 2023; R&D expenses $10.0M, up from $5.8M.
Cash and equivalents $69.5M; cash runway expected into 2026.
Phase 2a RIVER trial (RCC) ~80% enrolled; topline data expected Q4 2024.
Phase 2b CORAL trial (IPF cough) sample size re-estimation expected Q4 2024; topline H1 2025.
Appointed Margaret Garin, MD, MSCR as VP of Clinical Development.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.